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Abstract: Fascaplysin, a natural product isolated from marine sponges, is a potential candidate for
the development of anti-cancer drugs. However, the mechanism underlying its therapeutic effect
of strengthening anti-cancer efficacy of other drugs is poorly understood. Here, we found that
fascaplysin increases phosphorylation of protein kinase B (PKB), also known as AKT, and adenosine
monophosphate-activated protein kinase (AMPK), which are considered therapeutic targets for
cancer treatment due to their anti-apoptotic or pro-survival functions in cancer. A cell viability assay
revealed that pharmacological suppression of AKT using LY294002 enhanced the anti-cancer effect of
fascaplysin in various cancer cells. Similarly, fascaplysin was observed to have improved anti-cancer
effects in combination with compound C, a selective AMPK inhibitor. Another challenge showed that
fascaplysin increased the efficacy of methotrexate (MTX)-mediated cancer therapy by suppressing
genes related to folate and purine metabolism. Overall, these results suggest that fascaplysin may
be useful for improving the anti-cancer efficacy of targeted anti-cancer drugs, such as inhibitors of
phosphoinositide 3-kinase AKT signaling, and chemotherapeutic agents, such as MTX.
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1. Introduction
Chemoresistance acquired by genetic evolution during cancer treatment is closely linked to cancer
recurrence and dissemination and patient death [1]. Overcoming chemoresistance is therefore an
important challenge in the reduction of cancer-related deaths.
Fascaplysin is isolated from marine sponges and exerts anti-cancer effects, including the suppression of
growth, angiogenesis, and metastasis in several cancer cells, through inhibition of cyclin-dependent
kinase 4 (CDK4) [2–5]. Recently, we reported that fascaplysin exerts anti-cancer effects through
the down-regulation of survivin and hypoxia inducible factor-1α (HIF-1α) by suppressing
mechanistic target of rapamycin (mTOR)-eukaryotic translation initiation factor 4E-binding
protein 1 (4EBP1)-mediated 5′-cap-dependent translation [5]. In addition, fascaplysin exerts
anti-angiogenic effects by suppressing vascular endothelial growth factor receptor 2 (VEGFR2) through
non-competitive inhibition of Asp-Phe-Gly (DFG)-out [6]. However, ways to improve the anti-cancer
efficacy of fascaplysin for clinical application are poorly understood.
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The activation of AKT signaling, which has pro-survival and anti-apoptotic functions, is commonly
observed in several cancers [7,8]. It is also known that reactivation of AKT signaling confers resistance
to chemotherapy using doxorubicin and etoposide [9]. Indeed, overexpression of AKT has shown that
cancer cells are more highly resistant to paclitaxel in ovarian cancer [10]. Based on this background,
it is becoming clear that selective inhibition of AKT signaling could improve the anti-cancer efficacy of
chemotherapeutic agents.
Adenosine monophosphate-activated protein kinase (AMPK), a major indicator of intracellular
energy status, is phosphorylated and activated under nutrient deprivation for effective energy
production [11,12]. AMPK-mediated autophagy in cancer could activate a cell survival mechanism
that is activated by energy deprivation, chemotherapy, and hypoxia [13]. Paradoxically, activation of
AMPK signaling often confers sensitivity to chemotherapeutic agents by promoting apoptosis [14].
Recently, a therapeutic approach has been described, by which pharmacological activation of AMPK
signaling enhances the anti-cancer effects of methotrexate (MTX) by suppressing folate and purine
metabolism [15,16]. AMPK signaling is therefore a potential target for decreasing cancer mortality.
In the present study, we identified that fascaplysin unexpectedly increases AKT and AMPK
phosphorylation. As activation of AKT and AMPK signaling causes resistance to anti-cancer therapy
through its anti-apoptotic function, we hypothesized that the suppression of AKT and AMPK signaling
may improve the anti-cancer efficacy of fascaplysin. Here, our results showed that LY294002, a selective
inhibitor of PI3K-AKT signaling, and compound C, an AMPK inhibitor, dramatically reduce cancer
cell growth when used in combination with fascaplysin. In addition, we found that fascaplysin is
sufficient to enhance the anti-cancer efficacy of MTX.
2. Results
2.1. Fascaplysin Increases AKT Phosphorylation and DNA Damage Signaling
The reactivation of anti-apoptotic or pro-survival signaling during cancer treatment causes poor
anti-cancer efficacy, due to chemoresistance [1]. To develop a strategy to improve the anti-cancer
efficacy of fascaplysin, we investigated the activation of anti-apoptotic or pro-survival signaling upon
fascaplysin treatment using a phosphorylated kinase proteome array. Unexpectedly, increased AKT
phosphorylation and DNA damage signaling molecules, such as phospho-Chk2 and phospho-p53,
were observed in fascaplysin-treated A375 melanoma cells (Figure 1A). To validate whether fascaplysin
increases AKT, Chk1, and Chk2 phosphorylation, we measured phosphorylation status them in
response to fascaplysin in A375, A2058, and H1975 which have shown suppressive effect of fascaplysin
on 4EBP1 and p70S6K1 phosphorylation in previous report [6]. Figure 1B shows that fascaplysin
strongly increased the phosphorylation of AKT, Chk1, and Chk2. These results suggest that AKT
phosphorylation could confer resistance to fascaplysin-induced cancer cell death.
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Figure 1. Fascaplysin increases AKT phosphorylation and DNA damage-induced signaling. (A) A375 
melanoma cells were incubated with fascaplysin or dimethyl sulfoxide (DMSO) control for 8 h, and 
300 μg of total cell lysate was reacted with a phosphorylated kinase proteome profiler membrane. 
Up- or down-regulated kinases were identified. (B) A375, A2058, and H1975 cells were cultured in 
the absence or presence of the indicated concentrations of fascaplysin for 8 h, and then proteins were 
analyzed by Western blotting. 
2.2. Suppression of AKT Activation Synergizes the Anti-Cancer Effects of Fascaplysin  
AKT has been considered a therapeutic target for overcoming chemoresistance, due to its anti-
apoptotic and pro-survival functions [8]. Indeed, the pharmacological suppression of AKT 
reactivation by rapamycin, an allosteric mTOR inhibitor, has been shown to improve the anti-cancer 
efficacy of rapamycin [17]. We therefore further examined whether pharmacological AKT inhibition 
using LY294002 enhances fascaplysin-induced cancer cell death. Figure 2A shows that the increased 
AKT phosphorylation upon fascaplysin or rapamycin treatment was significantly diminished by 
LY294002, a selective inhibitor of phosphoinositide 3-kinase (PI3K). Moreover, low concentrations of 
fascaplysin (0.5 μM) or rapamycin (0.5 μM) were sufficient to synergistically reduced cell viability 
approximately 50% in combination with LY294002, in A375 melanoma cells (Figure 2B). Consistently, 
increased anti-cancer effect upon combination with fascaplysin and LY294002 were observed in 
colorectal cancer (HCT116) and lung cancer (H1975) cell lines (Figure 2C). To show synergism of anti-
cancer effect upon combination with fascaplysin and LY294002, we calculated the combination index 
with series of concentration of fascaplysin (0.2, 0.5, 1 and 2 μM) and LY294002 (0.2, 0.5, 1 and 2 μM) 
in A375 melanoma cells (Figure 2D) using CalcuSyn software 2.1 [18]. These results suggest that the 
pharmacological suppression of AKT signaling, which is reactivated upon fascaplysin treatment, 
may improve the anti-cancer efficacy of fascaplysin.  
Figure 1. Fascaplysin increases AKT phosphorylation and DNA damage-induced signaling. (A)
A375 melanoma cells were incubated with fascaplysin or dimethyl sulfoxide (DMSO) control for 8 h,
and 300 µg of total cell lysate was reacted with a phosphorylated kinase proteome profiler membrane.
Up- or down-regulated kinases were identified. (B) A375, A2058, and H1975 cells were cultured in
the absence or presence of the indicated concentrations of fascaplysin for 8 h, and then proteins were
analyzed by estern blotting.
2.2. Suppression of AKT Activation Synergizes the Anti-Cancer Effects of Fascaplysin
AKT has been considered a therapeutic target for overcoming chemoresistance, due to its
anti-apoptotic and pro-survival functions [8]. Indeed, the pharmacological suppression of AKT
reactivation by rapamycin, an allosteric mTOR inhibitor, has been shown to improve the anti-cancer
efficacy of rapamycin [17]. We therefore further examined whether pharmacological AKT inhibition
using LY294002 enhances fascaplysin-induced cancer cell death. Figure 2A shows that the increased
AKT phosphorylation upon fascaplysin or rapamycin treatment was significantly diminished by
LY294002, a selective inhibitor of phosphoinositide 3-kinase (PI3K). Moreover, low concentrations of
fascaplysin (0.5 µM) or rapamycin (0.5 µM) were sufficient to synergistically reduced cell viability
approximately 50% in combination with LY294002, in A375 melanoma cells (Figure 2B). Consistently,
increased anti-cancer effect upon combination with fascaplysin and LY294002 were observed in
colorectal cancer (HCT116) and lung cancer (H1975) cell lines (Figure 2C). To show synergism of
anti-cancer effect upon combination with fascaplysin and LY294002, we calculated the combination
index with series of concentration of fascaplysin (0.2, 0.5, 1 and 2 µM) and LY294002 (0.2, 0.5, 1 and
2 µM) in A375 melanoma cells (Figure 2D) using CalcuSyn software 2.1 [18]. These results suggest that
the pharmacological suppression of AKT signaling, which is reactivated upon fascaplysin treatment,
may improve the anti-cancer efficacy of fascaplysin.
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Figure 2. Pharmacological targeting of fascaplysin-induced AKT phosphorylation enhances the anti-
cancer effect of fascaplysin. (A) A375 and HCT116 cells were pre-incubated with 10 μM of LY294002 
for 20 min, and were then further treated with 1 μM of fascaplysin or rapamycin for 8 h. Protein levels 
were analyzed by Western blotting. (B, C) A375 cells were pre-incubated with 10 μM of LY294002 for 
20 min, and were then treated with 0.5 μM of fascaplysin or rapamycin for 36 h. The cell viability 
upon treatment of fascaplysin and LY294002 were measured in HCT116 and H1975 cells. Cell viability 
was measured by using the crystal violet staining assay described in Methods and Materials. (D) A375 
cells were incubated with series of dose of fascaplysin and LY294002 for 48 h, and then cell viability 
was determined by crystal violet assay. The combination index of the synergistic effect of fascaplysin 
with LY294002 in A375 cells was calculated by the CalcuSyn software 2.1. Values are represented as 
the mean ± standard deviation (SD) of three independent experiments performed in triplicate; * p < 
0.05 and ** p < 0.01. 
2.3. Fascaplysin Causes Metabolic Stress and Increases AMPK Signaling  
We previously reported that fascaplysin induces apoptosis through activation of caspases 
cascade [6], which is closely linked to mitochondrial stress [19]. We therefore examined whether 
fascaplysin causes mitochondrial damage and metabolic stress. Figure 3A shows that fascaplysin 
increased mitochondrial depolarization. In addition, severe ATP depletion was observed upon 
fascaplysin treatment in A375, HCT116, and H1975 cancer cells (Figure 3B). As AMPK signaling is 
activated upon metabolic stress to prevent cell death [11,12], activation of AMPK was measured upon 
fascaplysin treatment. Figure 3C shows that fascaplysin dramatically increased phosphorylation of 
AMPK and its target kinase, acetyl-coA carboxylase (ACC). These results reveal that fascaplysin 
increases the activation of AMPK signaling, which may be associated with chemoresistance and 
adaptation to metabolic stress.  
Figure 2. Pharmacological targeting of fascaplysin-induced AKT phosphorylation enhances the
anti-cancer effect of fascaplysin. (A) A375 and HCT116 cells were pre-incubated with 10 µM of
LY294002 for 20 min, and were then further treated with 1 µM of fascaplysin or rapamycin for 8 h.
Protein levels were analyzed by Western blotting. (B,C) A375 cells were pre-incubated with 10 µM
of LY294002 for 20 min, and were then treated with 0.5 µM of fascaplysin or rapamycin for 36 h.
The cell viability upon treatment of fascaplysin and LY294002 were measured in HCT116 and H1975
cells. Cell viability was measured by using the crystal violet staining assay described in Methods
and Materials. (D) A375 cells were incubated with series of dose of fascaplysin and LY294002 for
48 h, and then cell viability was determined by crystal violet assay. The combination index of the
synergistic effect of fascaplysin with LY294002 in A375 cells was calculated by the CalcuSyn software
2.1. Values are represented as the mean ± standard deviation (SD) of three independent experiments
performed in triplicate; * p < 0.05 and ** p < 0.01.
2.3. Fascaplysin Causes Metabolic Stress and Increases AMPK Signaling
We previously reported that fascaplysin induces apoptosis through activation of caspases
cascade [6], which is closely linked to mitochondrial stress [19]. We therefore examined whether
fascaplysin causes mitochondrial damage and metabolic stress. Figure 3A shows that fascaplysin
increased mitochondrial depolarization. In addition, severe ATP depletion was observed upon
fascaplysin treatment in A375, HCT116, and H1975 cancer cells (Figure 3B). As AMPK signaling
is activated upon metabolic stress to prevent cell death [11,12], activation of AMPK was measured
upon fascaplysin treatment. Figure 3C shows that fascaplysin dramatically increased phosphorylation
of AMPK and its target kinase, acetyl-coA carboxylase (ACC). These results reveal that fascaplysin
increases the activation of AMPK signaling, which may be associated with chemoresistance and
adaptation to metabolic stress.
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Figure 3. Fascaplysin causes mitochondrial depolarization and ATP depletion, resulting in increased 
AMPK phosphorylation and activation. (A) A375 and HCT116 cells were incubated with 1 μM of 
fascaplysin or DMSO control for 8 h, and then cells were used to analyze mitochondrial 
depolarization. Mitochondrial potential was measured using a Muse™ Mitopotential assay kit and a 
Mini Flow Cytometry Muse™ Cell Analyzer, as described in Methods and Materials. Values are 
represented as the mean ± standard deviation (SD) of two independent experiments performed in 
triplicate; * p < 0.05. (B) A375, H1975, and HCT116 cells were cultured with various concentrations of 
fascaplysin or DMSO control for 8 h, and then cellular ATP levels were measured using an ATP assay 
kit as described in Methods and Materials. Relative ATP levels were normalized using total protein 
concentrations and compared to that of the DMSO control. Values are represented as the mean ± 
standard deviation (SD) of two independent experiments performed in triplicate; * p < 0.05. (C) A375 
or HCT116 cells were treated with the indicated concentrations of fascaplysin or DMSO for 8 h, and 
then protein levels were measured by Western blotting. 
2.4. Suppression of Fascaplysin-Induced AMPK Activation Synergizes Anti-Cancer Efficacy of Fascaplysin  
AMPK signaling has been also considered as a therapeutic target for overcoming resistance to 
anti-cancer drugs during cancer treatment [20,21]. Here, we examined whether targeting AMPK 
activation synergistically induces apoptosis in fascaplysin-treated cancer cells. Figure 4A shows that 
compound C was sufficient to block AMPK phosphorylation and activation upon fascaplysin 
treatment, as well as ACC phosphorylation. Moreover, compound C notably increased fascaplysin-
induced apoptosis in A375 and HCT116 cancer cells (Figure 4B), suggesting that the pharmacological 
suppression of fascaplysin-induced AMPK activation using a selective AMPK inhibitor, compound 
C, synergistically increases apoptosis of cancer cells. 
Figure 3. Fascaplysin causes mitochondrial l ri ti and ATP depletion, resulting in increased
AMPK phosphorylation and activation. ( ) 375 and T116 cells were incubated with 1 µM of
fascaplysin or DMSO control for 8 h, and then cells were used to analyze mitochondrial depolarization.
Mitochondrial potential was measured using a Muse™ Mitopotential assay kit and a Mini Flow
Cytometry Muse™ Cell Analyzer, as described in Methods and Materials. Values are represented as the
mean ± standard deviation (SD) of two independent experiments performed in triplicate; * p < 0.05;
(B) A375, H1975, and HCT116 cells were cultured with various concentrations of fascaplysin or DMSO
control for 8 h, and then cellular ATP levels were measured using an ATP assay kit as described in
Methods and Materials. Relative ATP levels were normalized using total protein concentrations and
compared to that of the DMSO control. Values are represented as the mean ± standard deviation (SD)
of two independent experiments performed in triplicate; * p < 0.05; (C) A375 or HCT116 cells were
treated with the indicated concentrations of fascaplysin or DMSO for 8 h, and then protein levels were
measured by Western blotting.
2.4. Suppression of Fascaplysin-Induced AMPK Activation Synergizes Anti-Cancer Efficacy of Fascaplysin
AMPK signaling has bee also considered as a therapeutic target for overcoming resistance to
anti-cancer drugs during cancer treatment [20,21]. Here, we examined whether targeting AMPK
activation synergistically nduces ap ptosis in fascaplysin-treated cancer cells. Figure 4A hows that
compound C was sufficient to bl ck AMPK phosphorylation and activati n upo fascaplysin treatment,
as well as ACC phosphoryl tion. Moreover, compound C notably increased fascaplysin-induced
apoptosis in A375 and HCT116 cancer cells (Figure 4B), suggesting that t e pharmacological
suppression of fascaplysin-induced AMPK activation using a selective AMPK inhibitor, compound C,
synergistically increases apoptosis of cancer cells.
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Figure 4. Suppression of fascaplysin-induced AMPK activation enhances the anti-cancer effect of 
fascaplysin. (A) A375, HCT116, and H1975 cells were pre-incubated with 5 μM of compound C for 10 
min, and were then further treated with 1 μM of fascaplysin for 6 h. The protein levels were measured 
by Western blotting. (B) Compound C (5 μM) pre-treated A375 or HCT116 cells were further 
incubated with fascaplysin (1 μM) for 24 h, and then apoptotic cell numbers were measured using a 
Muse™ Annexin-V assay kit and a Mini Flow Cytometry Muse™ Cell Analyzer. Values are 
represented as the mean ± standard deviation (SD) of three independent experiments performed in 
duplicate; * p < 0.05 and ** p < 0.01. 
2.5. MTX Enhances the Anti-Cancer Efficacy of Fascaplysin  
Previous reports have shown that the activation of AMPK signaling using 5-aminoimidazole-4-
carboxamide ribonucleotide, known as AICAR, can improve MTX-based cancer therapy via the 
suppression of folate and purine metabolism [15,16]. Here, we further investigated whether 
fascaplysin suppresses the expression of genes related to folate and purine metabolism. Figure 5A 
shows that fascaplysin dramatically decreased the expression of such genes, including 
methylenetetrahydrofolate dehydrogenase (NADP+-dependent) 1-like (MTHFD1L), 5-
methyltetrahydrofolate-homocysteine methyltransferase (MTR), dihydrofolate reductase (DHFR) 
and methylenetetrahydrofolate dehydrogenase 1 (MTHFD1). As folate and purine metabolism are 
essential biological processes that supply nucleotides as building blocks for cell proliferation, cancer 
cell viability upon combination treatment with fascaplysin and MTX was measured. Figure 5B shows 
that MTX synergistically decreased cell viability by approximately 40–50% upon fascaplysin 
treatment in A375 and HCT116 cells. Consistent with this, fascaplysin-induced cancer cell was 
significantly increased approximately 20% by the addition of MTX (Figure 5C). These results indicate 
that fascaplysin suppresses folate and purine metabolism, and that MTX is sufficient to improve the 
anti-cancer efficacy of fascaplysin.  
Figure 4. Suppre sion of fascaplysin-induced AMPK activation enhances the anti-cancer e fect of
fascaplysin. (A) A375, HCT 16, and H1975 cells w re pre-incubated with 5 µM of compound C for
10 mi , and were then further treated with 1 µM of fascaplysin for 6 h. Th protein lev ls w re
measured by Western blotting; (B) Compound C (5 µM) pre-treated A375 or HCT116 cells were further
incubated with fascaplysin (1 µ ) for 24 h, and then apoptotic ce l nu bers ere easured using a
use exin- assay kit and a Mini Flow Cytometry Muse™ Cell Analyzer. Values are represented
as the m an ± standard deviation (SD) of three independe t xperiments performed in duplicate;
* p < 0.05 and ** p < 0.01.
2.5. TX Enhances the Anti-Cancer Efficacy of Fascaplysi
Previous reports have sho n that the activation of A PK signaling using 5-aminoimidazole-4-
car i ribonucleotide, known as AIC R, can improve MTX-based cancer therapy via the suppression
of folate and purine metabolism [15,16]. Here, we further inv stigated whether fascaplysin suppresses
the expression of genes r lated to f late and purine metab lism. Figure 5A shows that fascaplysin
dramatically decre sed the expression of such genes, including methylenetetrahydrofolate dehydrogenase
(NADP+-d pendent) 1-like (MTHFD1L), 5-methyltetrahy rofolat - homocysteine methyltransferase
(MTR), dihydrof late reductase (DHFR) and methyl net trahydrofolate dehydrogenase 1 (MTHFD1).
As folate and purine metabolism are essential biological processes that supply nucleotides as building
blocks for cell proliferation, c ncer cell viability upon combination treatment with fascaplysin
and MTX was measured. Figure 5B shows that MTX synergistically d creased cell viability by
approximately 40–50% upon fascaplysin treatment in A375 and HCT116 cells. Consistent with this,
fascaplysin-induced cancer cell was significantly i creased approximately 20% by the addition of MTX
(Figure 5C). These r sults indicate that fascaplysin suppresses folate and purine m tabolism, and that
MTX is sufficient to improve the anti-cancer efficacy of fascaplysin.
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Figure 5. Anti-folate cancer therapy by methotrexate (MTX) enhances the anti-cancer effect of 
fascaplysin. (A) A375 cells were incubated with the indicated concentrations of fascaplysin or DMSO 
control for 24 h, and then mRNA levels were measured using quantitative real time (RT)-PCR. Values 
are represented as the mean ± standard deviation (SD) of three independent experiments performed 
in duplicate; * p < 0.05. (B) A375 and HCT116 cells were pre-incubated with 0.1 μM of MTX for 10 min, 
and were then further treated with 0.5 μM of fascaplysin or DMSO control for 24 h. Cell viability was 
measured using a crystal violet staining assay. Values are represented as the mean ± standard 
deviation (SD) of three independent experiments performed in triplicate; * p < 0.05. (C) A375 cells 
were pre-treated with 0.1 μM of MTX for 10 min, and were then further incubated with fascaplysin 
(0.5 μM) or DMSO control for 24 h. The apoptotic cell numbers were then measured: values are 
represented as the mean ± standard deviation (SD) of three independent experiments performed in 
duplicate; * p < 0.05 and ** p < 0.01. 
3. Discussion 
Fascaplysin, as a natural compound isolated from marine sponge, exhibits anti-cancer effects in 
multiple types of cancer cell, including small cell lung cancer [22], melanoma [23], and glioma [24] 
through suppression of CDK4-mediated cell cycle progression. However, it is still poorly understood 
whether fascaplysin could improve anti-cancer effects of chemotherapeutic drugs. In the present 
study, pro-survival or anti-apoptotic factors such as AKT and AMPK unexpectedly increased in 
fascaplysin-treated cancer cells. We also uncovered that fascaplysin sensitized melanoma, colorectal, 
and lung cancer cells to the apoptotic effects of chemotherapeutic agents or targeted anti-cancer 
drugs. Indeed, the reactivation of AKT was observed upon fascaplysin treatment. However, previous 
reports showed that fascaplysin decreases AKT phosphorylation in HL-60 leukemia cells [25]. 
Rapamycin, a well-established selective mTOR inhibitor, reactivates AKT via mammalian target of 
rapamycin complex 2 (mTORC2) signaling in several lung cancer cell lines, including A549, H358, 
and H460 but not HL-60 leukemia cells [26–28]. Fascaplysin is therefore believed to have similar 
effects as rapamycin, and the AKT reactivation upon fascaplysin treatment might be dependent on 
cellular context. Nevertheless, the precise molecular mechanism by which fascaplysin reactivates 
AKT should be further investigated. As hyperactivation of AKT signaling causes drug resistance 
during cancer treatment [8], we investigated and found that combining fascaplysin with LY294002 
largely reduced viability of A375 (melanoma), HCT116 (colorectal cancer), and H1975 (lung cancer) 
cells. As acquired resistance to LY294002, a targeted anti-cancer drug, has also been reported in 
Figure 5. Anti-folate cancer therapy by methotrexate (MTX) enhances the anti-cancer effect of
fascaplysin. (A) A375 cells were incubated with the indicated concentrations of fascaplysin or D S
control for 24 h, and then mRNA levels were measured using quantitative real time (RT)-PCR. Values
are represented as the ean standard deviation (S ) of three independent experiments performed in
duplicate; * p < 0.05; (B) A375 and CT116 cells ere pre-incubated ith 0.1 µ of TX for 10 min,
and were then further treated with 0.5 µM of fascaplysin or DMSO control for 24 h. Cell viability
was measured using a crystal violet staining assay. Values are represented as the ean ± standard
deviation (SD) of three independent experiments performed in triplicate; * p < 0.05; (C) A375 cells were
pre-treated with 0.1 µM of MTX for 10 min, and were then further incubated with fascaplysin (0.5 µM)
or DMSO control for 24 h. The apoptotic cell numbers were then measured: values are represented
as the mean ± standard deviation (SD) of three independent experiments performed in duplicate;
* p < 0.05 and ** p < 0.01.
3. Discussion
Fascaplysin, as a natural co pound isolated fro arine sponge, exhibits anti-cancer effects in
ultiple types of cancer cell, including s all cell lung cancer [22], elano a [23], and glio a [24]
throug suppressi of 4- e iate cell cycle progressi . o ever, it is still poorly understood
hether fascaplysin co ld i r e ti-ca cer ff cts f c t r tic r s. In the resent
study, r -s r ival r ti-a optotic factors such as ex ectedly increased in
fascaplysin-treated cancer cells. We also uncovered that fascaplysin sensitized melanoma, colorectal,
and l c cer cells to the apoptotic eff cts of chemotherapeutic agents or targeted anti-c cer drugs.
Indeed, th reactivation of AKT was observed upon fascaplysin treatment. However, previous rep rts
showed that fascaplysin decreases AKT phosphorylation in HL-60 leukemia cells [25]. Rapamycin,
a well-establish d selective mTOR inhibitor, reactivates AKT ia mammali n t rget of rapamycin
complex 2 (mTORC ) signaling in several lung cancer cell li es, including A549, H358, and H460
but not HL-60 leukemia cells [26–28]. Fascaplysin is therefore believed to have similar effects as
rapamycin, and the AKT reactivation upon fascaplysin treatment might be dependent on cellular
context. Nevertheless, the precise molecular mechanism by which fascaplysin reactivates AKT should
be further investigated. As hyperactivation of AKT signaling causes drug resistance during cancer
treatment [8], we investigated and found that combining fascaplysin with LY294002 largely reduced
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viability of A375 (melanoma), HCT116 (colorectal cancer), and H1975 (lung cancer) cells. As acquired
resistance to LY294002, a targeted anti-cancer drug, has also been reported in several cancers [1],
fascaplysin may be useful in improving the anti-cancer efficacy of PI3K-AKT-targeting drugs.
The intercalation of fascaplysin into double-stranded calf thymus DNA has been observed [29].
Moreover, a previous report showed that the non-planar tryptoline analog of fascaplysin,
N-(biphenyl-2-yl) tryptoline (BPT, 6), attenuates cancer cell growth by increasing p53 in vitro and
in vivo [30]. Consistent with these previous works, a marked increase in Chk2 and p53 phosphorylation
(which are closely linked to DNA damage) was observed in fascaplysin-treated cells.
Reduced intracellular ATP levels and mitochondrial membrane potential were observed in
A375, H1975, and HCT116 cancer cells. However, a previous report showed that fascaplysin,
as a cyclin-dependent kinase 4 (CDK4) inhibitor, increases the activity of PPARγ-coactivator-1α
(PGC1α). This occurs via the suppression of GCN5-mediated acetylation, without any cytotoxicity
in non-proliferative primary hepatocytes [31]. PGC1α is a master transcriptional coactivator for
mitochondrial biogenesis and the maintenance of energy balance in several metabolic tissues [32].
However, our findings show that fascaplysin causes metabolic stress, with decreased mitochondrial
membrane potential and intracellular ATP levels. Thus, we speculate that fascaplysin could selectively
kill cancer cells but not normal differentiated cells, through induction of metabolic stress and apoptosis.
Consistent with ATP depletion, AMPK phosphorylation was observed in fascaplysin-treated cancer
cells. AMPK activation under metabolic stress helps overcome the stress [11,12]. In addition,
AMPK-mediated autophagy confers resistance to several anti-cancer drugs [13,20,21]. It was therefore
thought that AMPK activation may confer resistance to fascaplysin-induced apoptosis through
autophagy and metabolic compensation. In this study, we found that pharmacological inhibition
of AMPK using compound C synergistically enhanced fascaplysin-induced apoptosis in A375 and
HCT116 cancer cells. Thus, our results suggest that the combination of fascaplysin with AMPK
inhibitor may effectively suppress cancer growth.
One-carbon-based folate and purine metabolism supports building blocks for maintaining
intracellular nucleotides [33]. MTX, a potent inhibitor of dihydrofolate reductase (DHFR), an essential
enzyme for folate metabolism, functionally reduces the biosynthesis of purines and consequently DNA
synthesis [33]. Although MTX is an effective therapeutic agent for osteosarcoma and breast cancer,
drug resistance with increased DHFR gene expression has been observed in several cancers [34]. It has
recently been reported that the suppression of folate and purine metabolism by AMPK activation
synergistically increases the anti-cancer efficacy of MTX [15]. In this study, we found that fascaplysin
suppressed the expression of genes related to folate and purine metabolism, such as MTR and DHFR.
Importantly, fascaplysin sensitized cancer cells to the apoptotic effect of MTX. Notably, our results
suggest that fascaplysin has potential as a drug to overcome resistance to MTX-based cancer treatment.
Taken together, our results detail the several beneficial effects of fascaplysin, which allow it to
overcome drug resistance for cancer treatment: (1) fascaplysin sensitizes cells to the anti-cancer
effect of AKT inhibition-based cancer treatment; (2) fascaplysin causes metabolic stress with
decreased intracellular ATP levels and synergistically increases cancer cell apoptosis upon AMPK
inhibitor treatment; and (3) fascaplysin suppresses the expression of several folate and purine
metabolism-related genes, such as MTR and DHFR, and sensitizes cells to apoptosis caused by MTX.
4. Materials and Methods
4.1. Reagents and Antibodies
Fascaplysin, Compound C, and MTX were purchased from Selleck Chemicals (Houston, TX,
USA). Rapamycin and LY294002 were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
For Western blotting, antibodies against phospho-AMPKα (CST-2535), total-AMPKα (CST-5831),
phospho-AKT-S473 (CST-4060), phospho-AKT-T308 (CST-13038), total-AKT (CST-4691), phospho-ACC
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(CST-11818), total-ACC (CST-3676), and β-tubulin (sc-9104) were purchased from Cell Signaling
Technology (Danvers, MA, USA) and Santa Cruz Biotechnology (Dallas, TX, USA).
4.2. Cell Culture and Cell Viability Assay
Human melanoma (A375 and A2058), lung cancer (H1975), and colorectal cancer (HCT116) cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with fetal bovine serum (10%) (Thermo Fisher Scientific, Waltham, MA,
USA). Cell viability was measured by crystal violet staining and analysis [5]. The incubated cells for the
various experimental conditions were fixed using formaldehyde and stained with 0.5% crystal violet
staining solution (Sigma Aldrich, St. Louis, MO, USA). To evaluate cell viability, crystal violet-stained
cells were solubilized using lysis buffer containing 1% sodium dodecyl sulfate (SDS), and then, optical
density was measured at 570 nm (OD570) using an absorbance reader (BioTek, Winooski, VT, USA).
4.3. Western Blotting
Total protein was extracted using lysis buffer (1% IGEPAL, 150 mM NaCl, 50 mM Tris-HCl
(pH 7.9), 10 mM NaF, 0.1 mM EDTA, and protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO,
USA), and then mixed with sample buffer containing SDS prior to electrophoresis [6]. Total protein
was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then
transferred to a PVDF membrane (EMD Millipore, Burlington, MA, USA). The transferred membranes
were incubated with primary antibodies (1:1000–10,000) at 4 ◦C overnight, and were then incubated
with secondary antibodies (1:10,000) for 1 h at room temperature. Protein signals were detected using
an enhanced chemiluminescence (ECL) Prime kit (GE healthcare, Pittsburgh, PA, USA).
4.4. Quantitative Real-Time PCR
Two micrograms of total RNA were isolated using TRIzol (Thermo Fisher Scientific, Waltham,
MA, USA) for cDNA synthesis [6]. The mRNA expression levels were measured using quantitative
real-time PCR with cDNA and SYBR Green PCR Master mixture (Thermo Fisher Scientific, Waltham,
MA, USA). The PCR primer sequences (5′-3′) were as follows: AGTCCTGG CATGGTGCTC and TGTG
CCAAGGGACTTCATCT for MTHFD1L; TTCACAAGCAGATGGTAGGC and GCTATGGTGGTCATG
GCTTT for MTR; AAATGAGCTCCTTGTGGAGG and ACCTGGTTCTCCATTCCTGA for DHFR; and
TTGATTTTTCAGTCTCGCCC and TATTGGTGGTGTCCATCGTG for MTHFD1.
4.5. Proteome Profiler Array
Before the phosphorylated-proteome analysis, 1 × 107 cells/ml were harvested and rinsed using
cold phosphate-buffered saline (PBS) (Sigma Aldrich, St. Louis, MO, USA), and then solubilized
in lysis buffer from a Human Phospho-Kinase Array Kit (R&D systems, Minneapolis, MN, USA).
The provided nitrocellulose membranes, conjugated to biotinylated antibodies against multiple types
of phospho-kinase proteins, were incubated with 300 µg of cell lysate, overnight at 4 ◦C. After the
primary antibody reaction, the samples were washed using 20 mL of 1× wash buffer for 10 min
at room temperature, and then the membranes were incubated with streptavidin-HRP (1:10,000)
in 1× array buffer for 30 min at room temperature. Protein signals were then detected using a
ChemiReagent Mixture.
4.6. Apoptosis Assays
Apoptosis assays were performed using Muse™ Annexin V & Dead Cell kit reagent (EMD
Millipore, Burlington, MA, USA). Cells were cultured at a density of 1 × 105 cells in six-well cell
culture plates. After stabilization, cells were incubated for 24 h with fascaplysin, compound C, or
MTX. Cells were washed with cold PBS, and then adherent cells were collected into a fresh tube
using trypsin-EDTA (0.25%). Cell pellets were resuspended in 1 mL of fresh medium, and then the
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resuspended cells (100 µL) were incubated for 20 min with Muse™ Annexin V & Dead Cell kit reagent.
After the reaction, all samples were analyzed using a Mini Flow Cytometry Muse™ Cell Analyzer
(EMD Millipore, Burlington, MA, USA).
4.7. Mitochondrial Membrane Potential Assay
Mitopotential Assays were performed using a Muse® Mitopotential assay kit. Cells were cultured
at 1 × 105 cells per well in six-well cell culture plates. They were treated with fascaplysin (1 µM) for
24 h, and then were washed with cold PBS. Adherent cells were collected in a fresh tube, and the cell
pellet was then washed and resuspended in 1× assay buffer from the assay kit. The resuspended cells
(100 µL) were incubated with 95 µL of Mitopotential working solution and 5 µL of 7-AAD reagent.
Mixed samples were incubated for 20 min in an incubator maintained at 37 ◦C. After the reaction,
mitochondrial potential and cell numbers were analyzed using a Mini Flow Cytometry Muse™ Cell
Analyzer (EMD Millipore, Burlington, MA, USA).
4.8. ATP Assay
To measure intracellular ATP levels, 1 × 105 cells were seeded in six-well cell culture plates.
After stabilization for 24 h, cells were incubated with a range of concentrations of fascaplysin for
8 h. Cells were harvested and solubilized in 100 µL ATP assay buffer from an ATP Colorimetric/
Fluorometric assay kit (Biovision, CA, USA). The solubilized samples were transferred into 96-well
plates, and then mixed with 50 µL of ATP reaction solution, including an ATP probe and a developer.
After incubation for 30 min at room temperature with protection from light, sample absorbance was
measured at 570 nm using an absorbance reader (BioTek, Winooski, VT, USA).
4.9. Statistical Analysis
An unpaired Student’s t-test for two experimental comparisons and one-way ANOVA with
Tukey post-test for multiple comparisons were used for data analysis. Data are represented as
mean ± standard deviation (SD) values, which were considered statistically significant when p < 0.05.
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